Table 1.
Indications of the six currently approved monoclonal antibodies in the treatment of cancer (as of May 2018).
| Monoclonal antibody | Target | FDA/EMA-approved indications |
|---|---|---|
| Ipilimumab | CTLA-4 | Melanoma |
| Nivolumab | PD-1 | Melanoma, NSCLC, RCC, urothelial carcinoma, MSI-high/dMMR CRC, HCC, Hodgkin's lymphoma, HNSCC |
| Pembrolizumab | PD-1 | Melanoma, NSCLC, HNSCC, urothelial carcinoma, Hodgkin's lymphoma, MSI-high cancer, gastric/gastroesophageal cancer |
| Avelumab | PD-L1 | Merkel cell carcinoma, urothelial carcinoma |
| Atezolimumab | PD-L1 | Urothelial carcinoma, NSCLC |
| Durvalumab | PD-L1 | Urothelial carcinoma, NSCLC |
| Combined treatment with ipilimumab and nivolumab | CTLA-4/PD-1 | Melanoma, RCC |
CRC, colorectal cancer; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; dMMR, DNA mismatch repair deficiency; MSI, microsatellite instability; NSCLC, non-small-cell lung carcinoma; PD-1, programmed cell death protein; PD-L1, programmed death-ligand 1; RCC, renal cell carcinoma.